Prof Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.

A recent article by Zaki A. Sherif states that there is a proven lack of a full understanding about NAFLD and NASH. It can adversely impact patients, health professionals, health providers, and researchers alike. The biggest challenge is to increase awareness and improve education.

The aim of this very interesting study by L. Serfaty et al. was to assess the prevalence and riskfactors of NAFLD and associated liver fibrosis in a French population-based cohort (118, 664participants) by using using the Fatty Liver Index and Forns Index.

Almost 10,000 hepatologists and hepatology heath care professionals, researchers and clinicians, gathered in Boston to exchange the latest liver disease information. NASH and NAFLD were an integral component of this international scientific forum.

The Congress explored the relationship between Diabetes, NAFLD and NASH. Key communications feature an EASD/EASL Symposium on Friday, 20 September 2019 entitled “Is NAFLD a risk for health in the context of diabetes?” covering: Metabolic NAFLD; Genetic NAFLD; NAFL vs NASH, diagnosis and treatment: a hepatologist's perspective.

The author describes current knowledge of the role of PPARs in the regulation of whole-body energy metabolism and several examples of food factors that act as ligands of PPARs, which may be useful in the management of obesity and the accompanying energy metabolism abnormalities.

A recent article by Dr Adel Hammoutene and Prof Pierre-Emmanuel Rautou from Paris, France sheds light on the role of Liver sinusoidal endothelial cells (LSECs). improving LSEC health seems to be an interesting approach to prevent NAFLD progression and complications.

Pediatric Fatty Liver Disease: reports of NAFLD in patients as young as 2 years of age documented in an article by Dr Ajay Jain, Department of Pediatrics, saint louis university, in the USA..

The Congress Spotlight this year is Global Cardiovascular Health. Organised together with the World Heart Federation that highlighted differences in prevalence, clinical manifestations, prevention strategies, diagnostic modalities and management of cardiovascular diseases around the world. More than 30 000 healthcare professionals attended.

Prof. Sven Francque, Chair of the PanNASH initiative reviews the current management options in NASH and the many molecules in development. It sheds light on the rationale for PPAR agonists as a promising and very valuable therapeutic option with systemic potential, for what happens in the liver and outside of the liver.